New Zealand markets closed

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
25.52+0.85 (+3.45%)
At close: 04:00PM EDT
24.86 -0.66 (-2.59%)
After hours: 05:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close24.67
Open24.56
Bid25.51 x 100
Ask25.56 x 100
Day's range24.51 - 25.85
52-week range4.82 - 26.24
Volume1,195,060
Avg. volume1,220,221
Market cap2.034B
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-2.91
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est46.71
  • PR Newswire

    Avidity Biosciences to Participate in Upcoming Investor Conferences

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:

  • PR Newswire

    Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci

  • GuruFocus.com

    Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)

    Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 shares of the company on March 13, 2024, according to a recent SEC filing.